Prokineticin 1 is up-regulated by insulin in decidualizing human endometrial stromal cells

Dorina Ujvari a, * , Ivika Jakson a, b , Cecilia Oldmark a , Sanaz Attarha c , Twana Alkasalias d , e , Daniel Salamon a , Sebastian Gidlöf a, b, f , Angelica Lindén Hirschberg a, b

a Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
b Department of Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden
c Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
d Department of Microbiology, Tumour, and Cell Biology, Karolinska Institutet, Stockholm, Sweden
e Department of Biology, College of Science, Salahaddin University, Irbil, Kurdistan-Iraq
f Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

Received: February 7, 2017; Accepted: June 3, 2017

Abstract

Prokineticin 1 (PROK1), a hypoxia-regulated angiogenic factor, has emerged as a crucial regulator of embryo implantation and placentation. Dysregulation of PROK1 has been linked to recurrent pregnancy loss, pre-eclampsia, foetal growth restriction and preterm birth. These pregnancy complications are common in women with obesity and polycystic ovary syndrome, i.e. conditions associated with insulin resistance and compensatory hyperinsulinaemia. We investigated the effect of insulin on PROK1 expression during in vitro decidualization. Endometrial stromal cells were isolated from six healthy, regularly menstruating women and decidualized in vitro. Insulin induced a significant dose-dependent up-regulation of PROK1 on both mRNA and protein level in decidualizing endometrial stromal cells. This up-regulation was mediated by hypoxia-inducible factor 1-alpha (HIF1α) via the phosphatidylinositol 3-kinase (PI3K) pathway. Furthermore, we demonstrated that PROK1 did not affect the viability, but significantly inhibited the migration of endometrial stromal cells and the migratory and invasive capacity of trophoblast cell lines. This in vitro study provides new insights into the regulation of PROK1 by insulin in human decidualizing endometrial stromal cells, the action of PROK1 on migration of endometrial stromal cells, as well as migration and invasion of trophoblasts. We speculate that hyperinsulinaemia may be involved in the mechanisms by which PROK1 is linked to placenta-related pregnancy complications.

Keywords: PROK1 • EG-VEGF • insulin • endometrium • decidualization • trophoblast • migration • invasion

Introduction

The tightly coordinated decidual transformation is indispensable for the formation of a functional feto-maternal interface in order to successfully establish and maintain pregnancy. The central roles of decidualization are the protection of feto-maternal interface against oxidative stress, local suppression of maternal immune response and control of extravillous trophoblast migration and invasion [1]. The latter is mediated, at least in part, by a recently discovered hypoxia-regulated angiogenic factor PROK1, or alternatively named endocrine gland-derived vascular endothelial growth factor (EG-VEGF).

PROK1 has been described in the human endometrium throughout the menstrual cycle in the stroma, glandular epithelium and endothelial cells with increasing levels in the secretory phase [2]. Furthermore, PROK1 expression is significantly increased in first trimester decidua, compared with non-pregnant endometrium [3]. PROK1 is expressed in the placenta and is predominantly regulated by oxygen tension. In the hypoxic period of placentation development in the first trimester, increased level of placental PROK1 promotes proliferation of anchoring cytotrophoblasts and formation of trophoblastic plugs in the maternal spiral arteries [4, 5]. These trophoblastic plugs protect the developing placenta and embryo from highly oxygenated maternal blood and early oxidative damage. Placental PROK1 level declines after week 10–12 of pregnancy as the oxygen tension increases, facilitating deeper invasion of trophoblasts and remodelling of the maternal spiral arteries in order to supply the developing foetus [5, 6]. Impaired invasion and thin or fragmented trophoblastic plugs have been associated with early pregnancy loss, while poor invasion of maternal vessels has been correlated to both pre-eclampsia and foetal growth restriction [4, 6–9].

*Correspondence to: Dorina UJVARI
E-mail: dorina.ujvari@ki.se

© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
PROK1 was shown to be up-regulated by the hypoxia-inducible factor 1 (HIF1) in human placenta and human adrenal carcinoma cell lines and by human chorionic gonadotrophin in human placenta [5, 8, 10]. HIF1 is a basic helix-loop-helix transcription factor composed of two subunits, HIF1α and HIF1β. The latter is constitutively expressed, whereas HIF1α expression is up-regulated predominantly by hypoxia. Under normoxia, HIF1α is rapidly ubiquitinated by the von Hippel-Lindau tumour suppressor E3 ligase complex and subjected to proteasomal degradation [11]. HIF1α was shown to be up-regulated in luteal phase endometrium in both the stromal and the epithelial cells compared to the proliferative phase of the menstrual cycle [12]. It was demonstrated previously in a variety of cell types, but not in endometrial stromal cells, that HIF1α can be regulated not only by hypoxia but also by insulin and other growth factors under normoxic conditions, mainly by up-regulating HIF1α protein expression or preventing it from proteasomal degradation [13–16]. It was also shown in arising retinal pigment epithelia cell line 19 and primary rat hepatocytes, that HIF1α could be induced by insulin via the PI3K pathway [13, 17].

Insulin resistance leading to secondary hyperinsulinemia has been suggested to be of importance for pregnancy complications including miscarriage, recurrent pregnancy loss and preeclampsia in metabolic disorders such as polycystic ovary syndrome (PCOS) and obesity [18–31]. However, the underlying mechanisms are poorly understood.

We have recently reported data suggesting adverse effect of insulin on endometrial function and in vitro decidualization [32, 33]. In this in vitro study, we aimed to investigate the effect of insulin on the regulation of PROK1 in primary decidualizing human endometrial stromal cells, as well as the effect of PROK1 on migration of human endometrial stromal cells and migration and invasion of trophoblast cells.

Materials and methods

Subjects

Endometrial biopsies were collected under local anaesthesia with an endometrial suction curette (Pipet Curet; CooperSurgical, Trumbull, Connecticut, USA) from six regularly cycling, non-smoking healthy volunteers at cycle day 5–9. All participants were between 18 and 35 years with a body mass index ranging 19–28. Exclusion criteria were hormonal medication within 3 months prior to examination, current chronic disease, endocrine disorder or continuous medication. All women gave their written informed consent, and the Regional Ethical Committee in Stockholm approved the study (Dnr 2008/865-32).

Isolation of human endometrial stromal cells

Isolation of endometrial stromal cells was carried out as previously described [33]. Purity of stromal cells was ensured by sequential culturing and assessed by cytokeratin and CD10 staining for epithelial and stromal cells, respectively.

Culture conditions

Endometrial stromal cells were seeded in six-well Costar plates (Sigma-Aldrich, St. Louis, Missouri, USA) and cultured in DMEM/F12-Glutamax (Thermo Fischer Scientific, Waltham, Massachusetts, USA) supplemented with 10% heat-inactivated foetal bovine serum (HI-FBS) (Sigma-Aldrich) and 0.2% penicillin-streptomycin (Sigma-Aldrich) until ~80% confluency. In vitro decidualization was performed with a well-established procedure, as described previously [33, 34]. Briefly, media were changed to phenol red-free DMEM/F12 (Thermo Fischer Scientific), supplemented with 2% charcoal-stripped foetal bovine serum (Sigma-Aldrich) and 0.2% penicillin-streptomycin. To investigate the kinetics of decidualization, we treated the cells with 1 μM medroxyprogesterone-17-acetate (MPA) (Sigma-Aldrich) and 0.5 mM N6, 2’-O-dibutyryladenosine cAMP (db-cAMP) (Sigma-Aldrich) for 3 and 6 days. In order to clarify the contribution of each of MPA and db-cAMP to induce decidualization, endometrial stromal cells were treated with 1 μM MPA, 0.5 mM db-cAMP or combined treatment of MPA and db-cAMP for 6 days. To investigate the effect of insulin on PROK1 during decidualization, cells were treated with 1 μM MPA and 0.5 mM db-cAMP to induce decidualization for 6 days in the presence or absence of 5, 50 or 500 nM insulin (Sigma-Aldrich).

To test whether wortmannin, a PI3K inhibitor, could block the effect of insulin, stromal cells were pre-decidualized for 3 days and then pre-treated according to previous publications [35, 36] with 500 nM wortmannin (Sigma-Aldrich) for 1 hr prior to treatment with 100 nM insulin for 2 days in the presence of decidualization agents db-cAMP and MPA. To evaluate the involvement of HIF1α in the regulation of PROK1 by insulin, stromal cells were pre-decidualized for 3 days and then pre-treated with 5 nM of echinomycin (Merck Millipore, Darmstadt, Germany), a HIF1α inhibitor, for 1 hr prior to addition of 100 nM insulin for 2 more days along with the decidualization agents db-cAMP and MPA. All the treatments were carried out under normoxic conditions. The culture media were renewed every 3 days. After treatments conditioned media were collected, and cells were harvested for RNA isolation. All the treatments have been performed at least twice.

RNA isolation, cDNA synthesis and RT-PCR

Total RNA was extracted, and cDNA was synthesized as described previously [32]. 10 ng cDNA was subjected to RT-PCR using TaqMan method. Ribosomal protein L13a (RPL13A) served as an internal control and was used to normalize gene expression levels. The employed TaqMan assays (Thermo Fischer Scientific) were Hs00951617_m1 for PROK1, Hs00168730_m1 for prolactin (PRL), Hs00236877_m1 for insulin-like growth factor binding protein 1 (IGFBP1) and Hs01926559_g1 for prolactin (PRL) for RPL13A. The reactions were run in a StepOnePlus™ Real-Time PCR system (Thermo Fischer Scientific), and gene expression levels were determined using the ΔΔCt method. The PCR efficiency of all amplicons was 90–100%, and all determinations were performed in triplicate. PROK1 was measured in cells from six healthy volunteers.

Enzyme-linked immunosorbent assay

Secreted PROK1 protein produced by the decidualizing stromal cells in the presence of 0, 5, 50 or 500 nM of insulin was measured from conditioned media using enzyme-linked immunosorbent assay (ELISA) (Abcam, Cambridge, UK) according to the manufacturer’s instruction.
Briefly, stromal cells were decidualized with 1 μM MPA and 0.5 mM db-cAMP in the presence or absence of insulin for 6 days. Media and treatment were renewed after 3 days, and the conditioned media collected on the 6th day were processed for ELISA. The experiment was performed from treatments using six healthy volunteers in duplicates.

**Cell viability analysis**

To assess cell viability, a MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay was used. Briefly, 10^4 primary endometrial stromal cells were seeded in 200 μl DMEM/F12-Glutamax supplemented with 10% HI-FBS and 0.2% penicillin–streptomycin in a 96-well plate. After 24 hrs, the cells were washed with 200 μl DMEM/F12 media and 100 μl phenol red-free DMEM/F12 media were added with or without 50 ng/ml PROK1 (Sigma-Aldrich), supplemented with 2% charcoal-stripped foetal bovine serum and 0.2% penicillin–streptomycin. Cell viability was determined after 24 hrs by labelling the cells with 10 μl MTT reagent for 4 hrs. The resulting formazan crystals, which correspond to the amount of viable cells, were solubilized by the addition of 100 μl 10% sodium dodecyl sulphate solution in tris-buffered saline (TBS). Cell viability was quantified by the measurement of the absorbance in a plate-reader with a 595-nm filter. Absorbance of the untreated cells was set to 100%, and the viability of treated cells was calculated accordingly. The experiments were run using cells from three healthy volunteers in quadruplicates.

**Wound healing assay**

Endometrial stromal cells were seeded in 12-well Costar plates (Sigma-Aldrich) and cultured in DMEM/F12-Glutamax (Thermo Fischer Scientific) supplemented with 10% HI-FBS and 0.2% penicillin–streptomycin until confluency. The cells were scratched with a 200-μl pipette tip, and the media were removed. The cells were washed twice with PBS to remove cell debris and 1 ml phenol red-free DMEM/F12 media was added with or without 50 ng/ml PROK1, supplemented with 2% charcoal-stripped foetal bovine serum and 0.2% penicillin–streptomycin. Microphotographs were taken with 40× magnification at 0 and 24 hrs with a Leica DFC420 C digital camera on a Nikon Eclipse TS 100 inverted microscope (Leica Microsystems, Wetzlar, Germany) with a Nikon DS-U1 digital camera (Leica Microsystems). In each well of a non-adherent round-bottom 96-well plate, 100 μl of this suspension containing 3000 cells was seeded and incubated at 37°C in 5% CO2. Twenty-four hours later, spheroids had formed and were used for the spheroid invasion assay. Spheroids were embedded using 100 μl of 6 mg/ml growth factor reduced Basement Membrane Extract (R&D Systems) diluted with serum-free RPMI 1640 media in the presence or absence of 50 ng/ml PROK1 in round-bottom, low-attachment 96-well plates and centrifuged for 5 min. at 300 g at 4°C. After the gel was solidified at 37°C, 100 μl complete media was added onto the top of the gel, and spheroids were incubated at 37°C in 5% CO2. Microphotographs were taken with 40× magnification daily for 5 days with a Leica DFC420 C digital camera on a Nikon Eclipse TS 100 inverted microscope. Photographs were analysed using ImageJ software. The spheroid invasion assay was performed in quintuplicates.

**Transwell migration assay**

The motility of AC-1M88 choriocarcinoma–trophoblast hybrid cells (DSMZ, Braunschweig, Germany) was assessed using cell culture inserts with 8-μm pores (Merck Millipore) in 24-well plates. AC-1M88 cells were starved for 24 hrs, and then 10^5 cells were plated to cell culture inserts in 200 μl serum-free F12 media with or without 50 ng/ml PROK1. 750 μl F12 media supplemented with 10% HI-FBS was added to the lower well. After 48 hrs of incubation, inserts were washed twice with PBS, and the cells were fixed in 4% of paraformaldehyde in PBS for 15 min. The cells were stained with 0.5% crystal violet for 20 min., and the non-migrated cells were removed with cotton swab from the upper side of the membrane. Photographs were taken with 40× magnification on a Nikon Eclipse TS 100 inverted microscope using a Leica DFC420 C digital camera. Adobe Photoshop was used to convert photographs to greyscale images, and particles were quantified by ImageJ software. The transwell migration assay was performed in quintuplicates.

**Statistical analysis**

Normality of the data was tested with the Kolgomorov–Smirnov test. Statistical analysis was performed by the one-way ANOVA or Friedman test followed by multiple comparisons, based on the distribution of the data, where each treatment group was tested against the untreated group. In the P3K and HIF1α inhibitory experiments, the insulin-treated groups were compared with their respective controls (decidual, decidual + solvent or decidual + inhibitor). Paired t-test was used to analyse the effect of PROK1 on the viability and migration of endometrial stromal cells. In the cases of transwell migration assay and spheroid invasion assay, unpaired t-test was used to analyse statistical significance between PROK1 treated and untreated samples. P < 0.05 was considered as significant.
Results

PROK1 is up-regulated upon decidualization

To test the effect of decidualization on the expression of PROK1 in human primary endometrial stromal cells, we treated the cells with MPA, db-cAMP or their combination for 6 days. We found that db-cAMP induced morphological transformation of the cells and up-regulated PROK1 and the decidualization markers PRL and IGFBP1, whereas MPA did not. The combination of MPA and db-cAMP also induced morphological transformation of the cells and enhanced up-regulation of PROK1 and the decidualization markers PRL and IGFBP1 compared to db-cAMP alone (Fig. S1A and B). Furthermore, we investigated the kinetics of decidualization in response to the combined use of MPA and db-cAMP and found that decidualization was apparent after 3 days, and even more enhanced after 6 days (Fig. S1C).

Insulin up-regulates PROK1 in decidualizing endometrial stromal cells

Proliferative phase-derived stromal cells were decidualized in the presence or absence of increasing doses of insulin, and relative gene expression level of PROK1 was measured. PROK1 was highly up-regulated by insulin in a dose-dependent fashion (ns at 5 nM, \( P < 0.05 \) at 50 nM, \( P < 0.001 \) at 500 nM) (Fig. 1A).

To verify whether insulin also regulates the protein expression of PROK1 in decidualizing endometrial stromal cells, secreted PROK1 was measured from conditioned media. The protein expression was also highly up-regulated by insulin in a dose-dependent manner (ns at 5 nM, ns at 50 nM, \( P < 0.01 \) at 500 nM) (Fig. 1B).

PROK1 is up-regulated by insulin via the induction of HIF1α

To test whether HIF1α is involved in the insulin-induced up-regulation of PROK1, we treated decidualizing stromal cells with 5 nM echinomycin, a HIF1α inhibitor, in the presence or absence of 100 nM insulin. We found that 5 nM echinomycin completely blocked insulin-induced up-regulation of PROK1 mRNA, meaning that insulin exerts its effect on PROK1 via HIF1α (Fig. 2).

Insulin regulates PROK1 through the PI3K pathway

To investigate whether insulin regulates PROK1 through the PI3K pathway, we blocked PI3K signalling with 500 nM wortmannin during the decidualization process in the presence or absence of insulin. PI3K inhibition resulted in an almost complete inhibition of insulin-induced up-regulation of PROK1 (Fig. 3). This suggests that the regulation of insulin on PROK1 is conveyed by the PI3K signalling pathway.

PROK1 does not influence viability of endometrial stromal cells

To test whether PROK1 has an effect on cell viability, i.e. proliferation and cell death, MTT assay was performed on undifferentiated...
PROK1 inhibited migration of endometrial stromal cells

To investigate whether PROK1 has an effect on the migration of endometrial stromal cells, we performed a wound healing assay on the undifferentiated endometrial stromal cells. Treatment with 50 ng/ml PROK1 slightly, but significantly reduced the migration of endometrial stromal cells after 24 hrs ($P < 0.05$) (Fig. 4B and C and Video S1 and S2).

PROK1 inhibits invasion of HTR-8/SVneo trophoblast spheroids

Spheroids were formed using HTR-8/SVneo cells and embedded into basement membrane extract in the presence or absence of 50 ng/ml PROK1. The area covered by individual spheroids was determined daily. We found that invasion of the spheroids was reduced by PROK1, which reached significance in comparison to controls after 3 days ($P < 0.05$) (Fig. 6A and B).

Discussion

This study is the first to show that insulin up-regulates gene and protein expression of the pro-angiogenic factor PROK1 in decidualizing human endometrial stromal cells. We furthermore demonstrated that insulin enhances PROK1 expression via HIF1α, a well-known
regulator of PROK1, and that the PI3K pathway is involved in insulin-induced up-regulation of PROK1. It was also shown here for the first time that PROK1 does not affect viability, however decreases migration of endometrial stromal cells, a process that is crucial for adequate embryo implantation. In addition, it was demonstrated that PROK1 restricts the migration of AC-1M88 trophoblast—
choriocarcinoma hybrid cells, as well as the invasion of HTR-8/SVneo trophoblast spheroids.

In this study, we demonstrated that PROK1 gene and protein expression are up-regulated during in vitro decidualization, and this is in agreement with the in vivo findings in human endometrium by others [2]. This up-regulation in decidualizing human endometrial stromal cells was even more enhanced by insulin in a dose-dependent manner. It must be noted that PROK1 gene expression level after in vitro decidualization showed high variety among the volunteers, and two volunteers showed remarkably higher inducibility of PROK1 in response to insulin. These variances might be due to genetic polymorphisms of PROK1 gene, as certain polymorphisms have been associated with different gene expression levels of PROK1 [39].

In the present study, we demonstrated that when decidualizing endometrial stromal cells were treated with a HIF1α inhibitor or a PI3K inhibitor under normoxic conditions, they both prevented insulin-induced up-regulation of PROK1. These findings are in agreement with previous publications on the ability of HIF1α to up-regulate PROK1 in other cell types [5, 10]. Our data also support previous findings on the possible effect of insulin on HIF1α and the involvement of the PI3K pathway in this process and suggest that insulin up-regulates PROK1 in decidualizing endometrial stromal cells via PI3K-mediated HIF1α induction [13–17].

We also demonstrated that PROK1 reduced the migratory capacity of endometrial stromal cells. It was previously reported that invasion of the embryonic trophoblast required motility of maternal endometrial stromal cells [38, 40–42]. Moreover, endogenous PROK1 may act in an autocrine manner in decidualizing endometrial stromal cells via the prokineticin receptor 1 (PROKR1) [43]. We speculate that PROK1 dysregulation may interfere with normal implantation by inhibiting the migration of endometrial stromal cells. We also demonstrated that PROK1 did not affect the viability, i.e. proliferation, cell death and metabolism of endometrial stromal cells significantly. Furthermore, the negligible enhancement by PROK1 on cell viability can

Fig. 6 Spheroid invasion assay using HTR-8/SVneo trophoblast cells with or without 50 ng/ml PROK1. (A) Representative microphotographs (40× magnification) were taken with a Leica DFC420 C digital camera on a Nikon Eclipse TS 100 inverted microscope and converted to greyscale image by Adobe Photoshop. (B) Total invaded area analysed by ImageJ software. Values are presented as means and standard deviations. *P < 0.05.
be resulted in an underestimation of restriction of migration of endometrial stromal cells by PROK1.

In this study, we could show that PROK1 significantly inhibits the migration of AC-1M88 trophoblast-choriocarcinoma cells. As wound healing assay proved to be challenging with AC-1M88 cells, because of the detachment of the whole cell layer when scratching, we performed transwell migration assay. We also demonstrated that invasion of HTR-8/SVneo spheroids is restricted by PROK1. It was previously shown that PROK1 inhibits migration of HTR-8/SVneo cells, invasion of placental villous explants and tube-like organization of HTR-8/SVneo cells [6]. The authors suggested that sustained PROK1 expression beyond 10–12 weeks of gestation might cause an inhibition of deeper invasion of the decidua by differentiating extravillous trophoblasts that might consequently lead to a failure in maternal spiral artery remodelling [6]. Furthermore, it was recently demonstrated that sustained PROK1 levels beyond the first trimester of gestation cause defects in placental organization and function, increase hypoxia and decrease trophoblast invasion in mice, leading to gestational hypertension and dysregulated maternal kidney function, typical symptoms of pre-eclampsia [44]. Our results further support the previous suggestion that PROK1 may restrict the migration and invasion of embryonic trophoblast cells into maternal decidua [6].

Metabolic disorders such as PCOS, obesity and insulin resistance are associated with elevated risk of both miscarriage, including recurrent pregnancy loss [19, 21–23, 27, 28] and pre-eclampsia [18, 30]. Furthermore, a direct relationship was suggested between hyperinsulinaemia—a condition that can be present in these metabolic disorders—and early pregnancy loss/recurrent miscarriage [20, 23, 26, 27, 31], as well as pre-eclampsia [24, 25, 29].

Based on our data, we hypothesize that maternal hyperinsulinaemia could increase decidua PROK1 expression that might lead to impaired invasion of extravillous trophoblasts in the first trimester of the pregnancy. Clinical studies have shown that certain polymorphisms of PROK1 and PROKR1 are associated with altered susceptibility for recurrent pregnancy loss [39, 45, 46]. It was also demonstrated that gene expression level of PROK1 is higher in decidualizing endometrial stromal cells from patients with recurrent pregnancy loss compared to controls. This could result in prolonged endometrial receptivity, i.e. a temporally unique sequence of factors that make the endometrium receptive to embryo attachment and implantation, allowing out-of-phase implantation in an unsupportive uterine environment [47–49].

A line of evidence suggests that impaired invasion of extravillous trophoblasts might trigger a number of events. The shallow invasion of extravillous trophoblasts in the first trimester of pregnancy was shown to impair remodelling of the maternal spiral arteries that was associated with foetal growth restriction and pre-eclampsia [50, 51], resulting in a relatively hypoxic milieu in the placenta [7, 52]. The relative placental hypoxia was demonstrated to dysregulate several angiogenic factors including VEGF [53]. It was shown that these factors are dysregulated, and branching of the placental vasculization is enhanced in pre-eclampsia [54, 55], suggesting that switch from branching to non-branching angiogenesis is disturbed in this pregnancy complication. PROK1 was shown to enhance tube-like formation of microvascular placental endothelial cells (HPEC), suggesting that PROK1 contributes to branching of the vascular tree [56]. Furthermore, maternal serum level of PROK1 was shown to be significantly higher in pre-eclampsia and foetal growth restriction than in normal pregnancies [4, 6].

Taken together, our data show for the first time that PROK1—a crucial factor in pregnancy complications such as recurrent pregnancy loss, pre-eclampsia, foetal growth restriction and spontaneous preterm birth—is up-regulated by insulin in decidualizing endometrial stromal cells. We demonstrate that PROK1 negatively influences three processes, which are suggested to be essential for successful implantation, placenta development and normal maintenance of the pregnancy, i.e. migration of endometrial stromal cells and migration and invasion of trophoblasts. Our results support the previous suggestions that hyperinsulinaemia might play a role in the mechanisms behind hypoxia-related pregnancy complications such as miscarriage and pre-eclampsia.

Acknowledgements

The authors thank Lotta Blomberg, Siv Rödin Andersson and Berit Legerstam at the Women's Health Clinical Research Unit for technical assistance. This work was supported by a grant from Swedish Research Council (a grant to A.L.H.) and Stockholm County Council (grants to A.L.H. and S.G.). D.U., I.J. and A.L.H. designed the study; A.L.H. and S.G. enrolled the participants; A.L.H., I.J. and S.G. took the endometrial biopsies; D.U., I.J., C.O., S.A., T.A. and D.S. performed the experiments; D.U., I.J., C.O., T.A. and D.S. analysed the data; D.U., T.A. and D.S. visualized the data; D.U. wrote the initial draft of the manuscript; and all authors have seen, reviewed and approved the final version of the manuscript.

Conflict of interest

The authors declare no conflict of interests.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Figure S1 A. Representative micrographs of undifferentiated stromal cells and cells in response to MPA (1 μM), db-cAMP (0.5 mM) and their combined treatment after 6 days were taken using an inverted microscope with 40× magnification. B. Relative gene expression levels of PRL, IGFBP1 and PROK1 based on three healthy volunteers in response to MPA (1 μM), db-cAMP (0.5 mM) and their combined treatment in endometrial stromal/decidualizing cells after 6 days. The values presented are medians and ranges (min-max). *P < 0.05 and **P < 0.01 in comparison to the control (stromal) value. C. Relative gene expression levels of PRL, IGFBP1 and PROK1 based on three healthy volunteers in response to decidualizing agents MPA (1 μM) and db-cAMP (0.5 mM) in endometrial stromal/decidual cells after 0, 3 and 6 days. The values presented are medians and ranges (min-max). *P < 0.05, **P < 0.01 and ***P < 0.001 in comparison to the control (stromal) value.
References

1. Kajihara T, Brouillet S, Murthi P, Hoffmann P, Saoudi Y, Benharouga M, et al. Expression and regulation of the angiogenic factor EG-VEGF and its receptors in human endometrium and its regulation by the proangiogenic mitogen-prokineticin-1 and its receptors in human endometrium across the menstrual cycle. J Cell Mol Life Sci 2010; 67: 1875–84.

2. Hoffmann P, Feige JJ, Alfaidy N, Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy. Endocrinology 2006; 147: 1067–84.

3. Alfaidy N, Hoffmann P, Brouillet S, et al. The multiple roles of EG-VEGF/PROK1 in normal and pathological placentation. Biomed Rep Int 2014; 2014: 451906.

4. Brouillet S, Hoffmann P, Chauvet S, et al. Revisiting the role of IC50: new regulation of the angiogenic factor EG-VEGF and its receptors. Cell Mol Life Sci 2012; 69: 1537–50.

5. Jauniaux E, Burton GJ. Villous histomorphometry and placental bed biopsy investigation in Type I diabetic pregnancies. Placenta 2006; 27: 468–74.

6. LeCouter J, Kovalski J, Foster J, et al. Identification of an angiogenic nitrososelective for endocrine gland endothelium. Nature 2001; 412: 677–84.

7. Jaakola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolly proline hydroxylation. Science 2001; 292: 468–72.

8. Critchley HO, Osei J, Henderson TA, et al. Hypoxia-inducible factor-1alpha expression in human endometrium and its regulation by prostaglandin E-series prostanoisid receptor 2 (EP2). Endocrinology 2006; 147: 744–53.

9. Treins C, Giorgetti-Peraldi S, Murdaca J, et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002; 277: 2795–81.

10. Wang F, Li SS, Segersvard R, et al. Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis. Am J Pathol 2007; 170: 469–77.

11. Zelzer E, Levy Y, Kahana C, et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J 1998; 17: 5087–94.

12. Zhou Q, Liu LZ, Fu B, et al. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 2007; 28: 28–37.

13. Kietzmann T, Samoylenko A, Roth U, et al. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 2003; 101: 907–14.

14. Bodnar LM, Hess RB, Markovic N, et al. The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol 2005; 15: 475–82.

15. Craig LB, Ke RW, Kuthe WH. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002; 78: 487–90.

16. Essah PA, Cheang KI, Nestler JE. The pathophysiology of miscarriage in women with polycystic ovary syndrome. Review and proposed hypothesis of mechanisms involved. Hormones 2004; 3: 221–7.

17. Fedorcsak P, Storeng R, Dale PO, et al. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet Gynecol Scand 2000; 79: 43–8.

18. Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metab Clin Exp 1999; 48: 1589–95.

19. Glueck CJ, Wang P, Goldenberg N, et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858–64.

20. Hamad RR, Eriksson MJ, Silveira A, et al. Decreased flow-mediated dilation is present 1 year after a pre-eclamptic pregnancy. J Hypertens 2007; 25: 2301–7.

21. Hauth JC, Cifton RG, Roberts JM, et al. Maternal insulin resistance and preeclampsia. Am J Obstet Gynecol 2011; 204: e1–e6.

22. Hassisoiu CA, Chicea R, Stamatian FV, et al. High fasting insulin levels and insulin resistance may be linked to idiopathic recurrent pregnancy loss: a case-control study. Int J Endocrinol 2013; 2013: 576926.

23. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524–9.

24. Lashen H, Fear K, Sturdee DW. Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. Hum Reprod 2004; 19: 1644–6.

25. Malek-Khosravi S, Kaboudi B. Insulin changes in preeclamptic women during pregnancy. Ann Saudi Med 2004; 24: 434–6.

26. Roos N, Sahlin L, Ekman-Ordeberg G, et al. Women with polycystic ovary syndrome (PCOS) are more likely to experience adverse pregnancy outcomes. A population-based study. Human Reprod 2010; 25: 153–4.

27. Wang Y, Zhao H, Li Y, et al. Relationship between recurrent miscarriage and insulin resistance. Gynecol Obstet Invest 2011; 72: 245–51.

28. Ujvari D, Hucliy M, Calaby A, et al. Life-style intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome. Hum Reprod 2014; 29: 1526–35.

29. Ujvari D, Jakson I, Babayeva S, et al. Dysregulation of in vitro decidualization of human endometrial stromal cells by insulin via transcriptional inhibition of forkhead box protein 01. PLoS One. 2017; 12: e0171004.

30. Frolova AI, O’Neill K, Moley KH. Dehydroepiandrosterone inhibits glucose flux through the pentose phosphate pathway in
human and mouse endometrial stromal cells. Preventing decidualization and implantation. Mol Endocrinol. 2011; 25: 1444–55.
35. Latifi RB, Hess AP, Tulac S, et al. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. J Clin Endocrinol Metab. 2006; 90: 1598–606.
36. Zeng GY, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin - Direct measurement in vascular endothelial cells. J Clin Invest. 1996; 98: 894–8.
37. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9: 671–5.
38. Gonzalez M, Neufeld J, Reimann K, et al. Expansion of human trophoblastic spheroids is promoted by decidualized endometrial stromal cells and enhanced by heparin-binding epidermal growth factor-like growth factor and interleukin-1 beta. Mol Hum Reprod. 2011; 17: 421–33.
39. Su MT, Huang JY, Tsai HL, et al. A Common Variant of PROK1 (V67I) Acts as a Genetic Modifier in Early Human Pregnancy through Down-Regulation of Gene Expression. Int J Mol Sci. 2016; 17: 162.
40. Grewal S, Carver J, Ridley AJ, et al. Human endometrial stromal cell rho GTPases have opposing roles in regulating focal adhesion turnover and embryo invasion in vitro. Biol Reprod. 2010; 83: 75–82.
41. Grewal S, Carver JG, Ridley AJ, et al. Implantation of the human embryo requires Rac1-dependent endometrial stromal cell migration. Proc Natl Acad Sci USA. 2008; 105: 16189–94.
42. Weimar CH, Mackton NS, Post Uiterweer ED, et al. The motile and invasive capacity of human endometrial stromal cells: implications for normal and impaired reproductive function. Human Reprod Update. 2013; 19: 542–57.
43. Cook IH, Evans J, Maldonado-Perez D, et al. Prokineticin receptor 1 (PROKR1) and the calcium/NFAT signalling pathway. Mol Hum Reprod. 2010; 16: 158–69.
44. Sergent F, Hoffmann P, Brouillet S, et al. Sustained Endocrine Gland-Derived Vascular Endothelial Growth Factor Levels Beyond the First Trimester of Pregnancy Display Pheno-typic and Functional Changes Associated With the Pathogenesis of Pregnancy-Induced Hypertension. Hypertension. 2016; 68: 148–56.
45. Su MT, Lin SH, Chen YC, et al. Genetic variants in PROKR1 and the cal-cineurin/NFAT signalling pathway. Mol Hum Reprod. 2010; 16: 158–69.
46. Su MT, Lin SH, Lee IW, et al. Polymorphisms of endothrin gland-derived vascular endothelial growth factor genes and its recep-tor genes are associated with recurrent pregnancy loss. Hum Reprod. 2010; 25: 2923–30.
47. Karaer A, Cigremis Y, Celik E, et al. Proki-neticin 1 and leukemia inhibitory factor mRNA expression in the endometrium of women with idiopathic recurrent pregnancy loss. Fertil Steril. 2014; 102: e1.
48. Saiker M, Teklenburg G, Molokhia M, et al. Natural Selection of Human Embryos: impaired Decidualization of Endometrium Disables Embryo-Maternal Interactions and Causes Recurrent Pregnancy Loss. PloS One. 2010; 5: e10287.
49. Salker MS, Naultyl J, Steel JH, et al. Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptiv-ity in women with recurrent pregnancy loss. PloS One. 2012; 7: e52525.
50. Kaufmann P, Black S, Huppertz B. Endovas-cular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003; 69: 1–7.
51. Pijnenborg R, Verbrugge L, Hanssens A. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006; 27: 939–58.
52. Genbacev O, Joslin R, Damsky C, et al. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest. 1996; 97: 540–50.
53. Kaufmann P, Mayhew TM, Charnock-Jones DS. Aspects of human fetoplacental vasculogen-esis and angiogenesis. II. Changes during normal pregnancy. Placenta. 2004; 25: 114–26.
54. Charnock-Jones DS, Kaufmann P, Mayhew TM. Aspects of human fetoplacental vascu-logenesis and angiogenesis. I. Molecular regulation. Placenta. 2004; 25: 103–13.
55. Mayhew TM, Charnock-Jones DS, Kaufmann P. Aspects of human fetoplacental vasculogenesis and angiogenesis. III. Changes in complicated pregnancies. Placenta. 2004; 25: 127–39.
56. Brouillet S, Hoffmann P, Benharouga M, et al. Molecular characterization of EG-VEGF-mediated angiogenesis: differential effects on microvascu-lar and macrovascular endothelial cells. Mol Biol Cell. 2010; 21; 2832–43.